NCT06953206View on ClinicalTrials.gov

Prospective, Long-term Evaluation of the SAPIEN 3 Ultra RESILIA Valve

Not yet recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

May 30, 2037

Study Completion Date

September 30, 2037

Conditions
Transcatheter Aortic Valve Replacement (TAVR)Aortic-StenosisAortic InsufficiencyDegenerative Valve Disease
Interventions
PROCEDURE

Transcatheter aortic valve (S3UR) replacement (TAVR)

Elective transfemoral TAVi procedure with S3UR valve.

Trial Locations (1)

32545

Heart and Diabetes Center North Rhine-Westphalia, Bad Oeynhausen

All Listed Sponsors
lead

Institut für Pharmakologie und Präventive Medizin

NETWORK

NCT06953206 - Prospective, Long-term Evaluation of the SAPIEN 3 Ultra RESILIA Valve | Biotech Hunter | Biotech Hunter